For research use only. Not for therapeutic Use.
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC)[1][2].
Gatipotuzumab (PankoMab) strongly binds to a short MUC1 peptide of 30 amino acids comprising 1.5 TRs when it is glycosylated with GalNAcα at the T of the PDTRP-sequence, but not if the same peptide is not glycosylated[2].
Gatipotuzumab (PankoMab) (1 h) has a high-affinity towards tumour cells (KD of 0.91, 3.03, 3.84 and 7.14 nM towards NM-D4, ZR75-1, MCF-7 and T-47D, respectively)[2].
Gatipotuzumab (PankoMab) (0-5 μg/mL; 4 h) shows specific anti-tumor antibody-dependent cell cytotoxicity activity[2].
| Catalog Number | I042092 |
| CAS Number | 1264737-26-9 |
| Purity | ≥95% |
| Reference | [1]. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6. [2]. Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006 Nov;55(11):1337-47. |
